Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PQ203
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears Phase I, Fast Track For ProteinQure’s PQ203 In US, Canada
Details : PQ203 is a novel Peptide Drug Conjugate composed of a peptide targeting the Sortilin receptor, being investigated for the treatment of triple negative breast cancer.
Product Name : PQ203
Product Type : Peptide-drug Conjugate
Upfront Cash : Inapplicable
August 07, 2025
Lead Product(s) : PQ203
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ProteinQure to Present Breakthrough Therapeutic for Triple-Negative Breast Cancer at AACR
Details : ProteinQure uses computational platforms to develop SORT1-targeting PDC, a peptide linked to a potent chemotherapeutic agent for breast cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable